Dyslipidemia Clinical Trials

84 recruitingLast updated: July 17, 2026

There are 84 actively recruiting dyslipidemia clinical trials across 26 countries. Studies span Not Applicable, Phase 1, Phase 3, Phase 4, Phase 2, Early Phase 1. Top locations include Seoul, South Korea, Beijing, Beijing Municipality, China, Athens, Georgia, United States. Updated daily from ClinicalTrials.gov.


Dyslipidemia Trials at a Glance

84 actively recruiting trials for dyslipidemia are listed on ClinicalTrialsFinder across 6 cities in 26 countries. The largest study group is Not Applicable with 35 trials, with the heaviest enrollment activity in Seoul, Beijing, and Athens. Lead sponsors running dyslipidemia studies include University of Georgia, Yonsei University, and CRISPR Therapeutics AG.

Browse dyslipidemia trials by phase

Treatments under study

About Dyslipidemia Clinical Trials

Looking for clinical trials for Dyslipidemia? There are currently 33 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Dyslipidemia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Dyslipidemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 84 trials

Recruiting
Not Applicable

Kodo Millet Porridge and Its Effects on Gut Health and Metabolic Syndrome

Insulin ResistanceMetabolic SyndromeObesity, Overweight+2 more
JSS MEDICAL COLLEGE, JSS ACADEMY OF HIGHER EDUCATION AND RESEARCH50 enrolled1 locationNCT07703371
Recruiting

A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

mixed dyslipidemiaPrimary Hypercholesterolemiia
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company2,000 enrolled163 locationsNCT06686615
Recruiting
Not Applicable

Effects of Pitavastatin or Combination of Pitavastatin and Ezetimibe on Glucose Metabolism Compared to AtoRvastatin in atheroscLerotic Cardiovascular Disease Patients With Metabolic Syndrome: The EZ-PEARL Randomized Trial

DyslipidemiasAtherosclerotic Cardiovascular Disease
Yonsei University250 enrolled1 locationNCT05705804
Recruiting
Not Applicable

Taiwan Green Propolis for Blood Lipids and Body Fat in Patients With MASLD

Obesity, OverweightMetabolic Dysfunction-Associated Steatotic Liver DiseaseNon-alcoholic Fatty Liver Disease NAFLD+1 more
Taipei Medical University60 enrolled1 locationNCT07692438
Recruiting
Phase 1

A Randomized, Open-label, Two-arm, Two-period, Multiple-dose, Study to Evaluate Pharmacokinetic Drug-drug Interaction, Safety and Tolerability of UIC202601 and UIC202602 in Healthy Volunteers

HypertensionDyslipidemia
Korea United Pharm. Inc.36 enrolled1 locationNCT07682948
Recruiting
Not Applicable

Uppsala Self-Screening of Cardiovascular Health

Diabetes MellitusCardiovascular DiseasesAtrial Fibrillation+3 more
Johan Sundström45,000 enrolled1 locationNCT07614659
Recruiting
Not Applicable

Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy

DyslipidemiasPeripheral Vascular DiseasesPeripheral Artery Disease
Brigham and Women's Hospital400 enrolled1 locationNCT06300450
Recruiting
Not Applicable

Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD

Cardiovascular DiseasesAtherosclerosisDyslipidemia+2 more
Yonsei University1,952 enrolled1 locationNCT07524101
Recruiting
Phase 3

Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days

Hypercholesterolaemiamixed dyslipidemia
A. Menarini International Licensing S.A.426 enrolled1 locationNCT07614958
Recruiting
Phase 1

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia

Healthy ParticipantsDyslipidemia
AstraZeneca136 enrolled6 locationsNCT06980428
Recruiting
Phase 1

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

HypercholesterolaemiaMetabolic DiseaseDyslipidemias+7 more
CRISPR Therapeutics AG90 enrolled18 locationsNCT07491172
Recruiting
Not Applicable

Effects of Nattokinase on Inflammation and Cardiovascular Risk Markers in Patients With Dyslipidemia

Cardiovascular DiseasesInflammationDyslipidemias
Universidade Federal Fluminense48 enrolled1 locationNCT06183307
Recruiting
Not Applicable

Smartwatch-based Intervention for Cardiovascular Health (SWITCH)

PrediabetesPrehypertensionOverweight/Obesity+1 more
Beijing Anzhen Hospital1,400 enrolled3 locationsNCT07372729
Recruiting
Phase 4

Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia

Diabetes Mellitus, Type 2AtherosclerosisDyslipidemias
Seoul National University Bundang Hospital105 enrolled1 locationNCT05365438
Recruiting
Phase 4

Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia

Diabetes Mellitus, Type 2AtherosclerosisDyslipidemia
Seoul National University Bundang Hospital56 enrolled1 locationNCT05365425
Recruiting

Psychosocial, Environmental, and Chronic Disease Trends in Puerto Rico

ObesityCardiovascular DiseasesMetabolic Syndrome+13 more
Harvard School of Public Health (HSPH)2,500 enrolled1 locationNCT03794531
Recruiting
Not Applicable

Goal Commitment and Proactive Health Behavior in Chronic Disease Patients

Diabetes MellitusHypertensionDyslipidemia
Xiong Juyang600 enrolled1 locationNCT07552571
Recruiting
Not Applicable

The SWITCH (Substitution of High With Low Ultra-processed Soy Protein Foods In a Guideline-based Diet inTervention for Cardiometabolic Health) Trial

Metabolic HealthHypertensionDiabetes Mellitus, Type 2+3 more
University of Toronto300 enrolled1 locationNCT06907862
Recruiting

Prevalence, Incidence and Risk Signature of Chronic Kidney Disease in Sub-Saharan Africa

ObesityCardiovascular DiseasesChronic Kidney Diseases+8 more
Swiss Tropical & Public Health Institute1,200 enrolled1 locationNCT05881447
Recruiting
Not Applicable

A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors

Diabetes MellitusObesityHypertension+2 more
University of Connecticut72 enrolled3 locationsNCT07238556